title: Inappropriate antidiuretic hormone secretion after high-dose thiotepa.
abstract: High-dose thiotepa has been successfully included in a variety of conditioning regimens for stem cell transplantation in hematological and solid neoplasms. Toxicity of high-dose thiotepa mainly manifests as profound myeloablation and some degree of liver damage. We report a case of inappropriate secretion of antidiuretic hormone (SIADH) in a patient with primary CNS lymphoma who underwent therapy with high-dose thiotepa.
authors.affiliation: Divisione Ematologia, Istituto di Semeiotica Medica, Università Cattolica Sacro Cuore, Rome, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Sica
authors.forename: S
authors.initials: S
authors.lastname: Cicconi
authors.forename: F
authors.initials: F
authors.lastname: Sorà
authors.forename: P
authors.initials: P
authors.lastname: Chiusolo
authors.forename: N
authors.initials: N
authors.lastname: Piccirillo
authors.forename: L
authors.initials: L
authors.lastname: Laurenti
authors.forename: E O
authors.initials: EO
authors.lastname: La Barbera
authors.forename: G
authors.initials: G
authors.lastname: Giordano
authors.forename: G
authors.initials: G
authors.lastname: Leone
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000139:chemically induced*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects*; D019172:Transplantation Conditioning / Q000009:adverse effects*
chemical_list: D013852:Thiotepa